Clinical Medicine Insights: Oncology (Dec 2014)

Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment

  • David Parker,
  • Marc-Antoine Belaud-Rotureau

Journal volume & issue
Vol. 2014, no. 8
pp. 145 – 152

Abstract

Read online

No abstracts available.